Global Gastrointestinal Stromal Tumors Market Projected To Grow Radiantly By 2030; Asserts MRFR Unleashing Industry Forecast

Pune, India, March, 2022 /MRFR Press Release/- Market Research Future published a Half-Cooked research report on “Global Gastrointestinal Stromal Tumors Market Research Report - Forecast to 2030” – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2030.

Gastrointestinal Stromal Tumors Market Highlights

One of the most common form of sarcoma is gastrointestinal stromal tumors (GIST) involving the gastrointestinal tract. Gastrointestinal stromal tumors can occur anyplace within the GI tract but is most often found in the stomach i.e. about in 40-70% of the cases and 20-30% in the small intestine. Every year approximately 11 to 20 million people worldwide are diagnosed with GIST.

The Gastrointestinal Stromal Tumors Market is projected to reach USD 3.29 Billion by 2030 at 7.20% CAGR during the forecast period 2023-2030.

The gastrointestinal stromal tumors market is expected to grow at a steady pace. The factors influencing the growth of the market include increasing prevalence of gastrointestinal diseases, increasing prevalence of cancer, increasing investments and funding in the field of life science research, increasing awareness among the people, growing geriatric population, changing reimbursement policies and various others. Furthermore, factors such as presence of misbranded and spurious drugs is hampering the growth of the market.

Global Gastrointestinal Stromal Tumors Market - Competitive Analysis

Characterized by the presence of several well-established and small players, the global market of gastrointestinal stromal tumors appears to be highly competitive and fragmented. With well-established market in the North America region major companies have their home in the region and generate maximum market share. These companies have expanded their operating unit in various other emerging regions as well. Moreover the other small and medium scale players are generating revenue from local market.

Bayer AG (Germany) Novartis AG (Switzerland), Immunicum AB (Sweden), F. Hoffmann-La Roche Ltd.(Switzerland), AB SCIENCES (FRANCE), Arog Pharmaceuticals, Inc. (U.S), Boston Biomedical, Inc. (U.S) are some of the prominent players at the forefront of competition in the Global Gastrointestinal Stromal Tumors Market and are profiled in MRFR Analysis.

There has been increasing development in the field of Gastrointestinal Stromal Tumors. Companies are keen in developing new products for the same. In November 2016, announced supplemental New Drug Application (sNDA) for Stivarga tablets had been submitted for the approval to the U.S. Food and Drug Administration (FDA) for the second-line systemic treatment of patients with unresectable hepatocellular carcinoma (uHCC). Hepatocellular carcinoma (HCC), is the most common form of liver cancer accounting for more than 70-85 percent of liver cancer across the world. Stivarga is already been approved for the treatment of patients with metastatic gastrointestinal stromal tumor (GIST), metastatic colorectal cancer (mCRC). Adding to this in June 2017, Bayer announced that the Committee for Medicinal Products for Human Use (CHMP) the European Medicines Agency recommended regorafenib (oral multi-kinase inhibitor) for the treatment of grownup patients with hepatocellular carcinoma (HCC) who have been previously treated with Nexavar. Regorafenib is the only treatment method that has been demonstrated a major improvement in overall survival in second-line hepatocellular carcinoma HCC patients who formerly had no other options for the treatment. The approval of European Commission on the commercial authorization is expected by the end of 2018.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Gastrointestinal Stromal Tumors Market Research Report

Global Gastrointestinal Stromal Tumors Market - Regional Analysis

Global gastrointestinal stromal tumors market is segmented on the basis of geographies or regions which mainly includes North America, Europe, Asia Pacific, and Middle East & Africa. North America is dominating the global market for gastrointestinal stromal tumors with more than 35% share of the total market in 2016. The major factor for the growth of the market include due to increasing prevalence of liver cancer. According to Centers for Disease Control and Preventation, every year in the U.S. about 22,000 men & 9,000 women get liver cancer, and more than 16,000 men & 8,000 women die from the same disease. The percentage of Americans who develop liver cancer has been rising from past few decades. More over the presence of major manufacturers in the region and the development for the products has been influencing the growth of the market.

Europe holds the second largest share of the global gastrointestinal stromal tumors market. Asia Pacific is the fastest growing gastrointestinal stromal tumors stimulation market across the globe. In Asia-Pacific there is wide range of opportunities for gastrointestinal stromal tumors market due to the presence of developing countries, major companies are grabbing these opportunities and expanding their presence in the region. Furthermore increasing research and development in this region has further enhanced the growth of the market.

The Middle East & Africa holds the least share of the global market due to limited availability of medical facilities. The UAE, Saudi Arabia, and Kuwait are expected to drive the Middle East & African market. Whereas, the African region is expected to witness a moderate growth.